Effects of SULT1A1 Copy Number Variation on Estrogen Concentration and Tamoxifen-Associated Adverse Drug Reactions in Premenopausal Thai Breast Cancer Patients: A Preliminary Study

  • Charoenchokthavee, Wanaporn (Department of Pharmacy Practice, Faculty of Pharmaceutical Science, Department of Medicine, Chulalongkorn University) ;
  • Ayudhya, Duangchit Panomvana Na (Department of Pharmacy Practice, Faculty of Pharmaceutical Science, Department of Medicine, Chulalongkorn University) ;
  • Sriuranpong, Virote (Medical Oncology Unit, Department of Medicine, Chulalongkorn University) ;
  • Areepium, Nutthada (Department of Pharmacy Practice, Faculty of Pharmaceutical Science, Department of Medicine, Chulalongkorn University)
  • Published : 2016.06.01


Tamoxifen is a pharmacological estrogen inhibitor that binds to the estrogen receptor (ER) in breast cells. However, it shows an estrogenic effect in other organs, which causes adverse drug reactions (ADRs). The sulfotransferase 1A1 (SULT1A1) enzyme encoded by the SULT1A1 gene is involved in estrogen metabolism. Previous research has suggested that the SULT1A1 copy number is linked with the plasma estradiol (E2) concentration. Here, a total of 34 premenopausal breast cancer patients, selected from the Thai Tamoxifen (TTAM) Project, were screened for their SULT1A1 copy number, plasma E2 concentration and ADRs. The mean age was $44.3{\pm}11.1years$, and they were subtyped as ER+/progesterone receptor (PR)+ (28 patients), ER+/PR- (5 patients) and ER-/PR- (1 patient). Three patients reported ADRs, which were irregular menstruation (2 patients) and vaginal discharge (1 patient). Most (33) patients had two SULT1A1 copies, with one patient having three copies. The median plasma E2 concentration was 1,575.6 (IQR 865.4) pg/ml. Patients with ADRs had significantly higher plasma E2 concentrations than those patients without ADRs (p = 0.014). The plasma E2 concentration was numerically higher in the patient with three SULT1A1 copies, but this lacked statistical significance.


  1. Berliere M, Duhoux FP, Dalenc F, et al (2013). Tamoxifen and ovarian function. PLoS ONE, 8, 66616.
  2. Del Re M, Michelucci A, Simi P, et al (2012). Pharmacogenetics of anti-estrogen treatment of breast cancer. Cancer Treat Rev, 38, 442-50.
  3. Dhingra K (1999). Antiestrogens-Tamoxifen, SERMs and Beyond. Invest New Drug, 17, 285-311.
  4. Dieudonne AS, Lambrechts D, Smeets D, et al (2014). The rs1800716 variant in CYP2D6 is associated with an increased double endometrial thickness in postmenopausal women on tamoxifen. Ann Oncol, 25, 90-5.
  5. Gjerde J, Geisler J, Lundgren S, et al (2010). Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer, 10, 313.
  6. Gjerde J, Hauglid M, Breilid H, et al (2008). Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol, 19, 56-61.
  7. Kallstrom A, Salme R, Ryden L, et al (2010). $17{\beta}$-Hydroxysteroid dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer. Eur J Cancer, 46, 892-900.
  8. Kiyotani K, Mushiroda T, Imamura CK, et al (2012). Doseadjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients. Breast Cancer Res Treat, 131, 137-45.
  9. Klein DJ, Thorn CF, Desta Z, et al (2013). PharmGKB summary: Tamoxifen pathway, pharmacokinetics. Pharmacogenet Genomics, 23, 643-7.
  10. Lonning P, Johannessen D, Lien E, et al (1995). Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol, 52, 491-6.
  11. Lorizio W, Wu AHB, Beattie MS, et al (2012). Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat, 132, 1107-18.
  12. Lum S, Woltering E, Fletcher W, et al (1997). Changes in serum estrogen levels in women during tamoxifen therapy. Am J Surg, 173, 399-402.
  13. Matsui S, Yasui T, Tani A, et al (2013). Associations of estrogen and testosterone with insulin resistance in pre- and postmenopausal women with and without hormone therapy. Int J Endocrinol Metab, 11, 65-70.
  14. Moyer AM, Suman VJ, Weinshilboum RM, et al (2011). SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen. Pharmacogenomics, 12, 1535-43.
  15. Westbrook K, Stearns V (2013). Pharmacogenomics of breast cancer therapy: An update. Pharmacol Ther, 139, 1-11.
  16. Yang G, Nowsheen S, Aziz K, et al (2013). Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol Ther, 139, 392-404.
  17. Yu X, Kubota T, Dhakal I, et al (2013). Copy number variation in sulfotransferase isoform 1A1 (SULT1A1) is significantly associated with enzymatic activity in Japanese subjects. Pharmgenomics Pers Med, 6, 19-24.

Cited by

  1. Tamoxifen vol.1643, pp.1, 2017,